This article needs additional citations for verification. (December 2020)
|Trade names||Myambutol, Etibi, Servambutol, others|
|Elimination half-life||3–4 hours|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||204.314 g·mol−1|
|3D model (JSmol)|
Ethambutol (EMB, E) is a medication primarily used to treat tuberculosis. It is usually given in combination with other tuberculosis medications, such as isoniazid, rifampicin and pyrazinamide. It may also be used to treat Mycobacterium avium complex, and Mycobacterium kansasii. It is taken by mouth.
Common side effects include problems with vision, joint pain, nausea, headaches, and feeling tired. Other side effects include liver problems and allergic reactions. It is not recommended in people with optic neuritis, significant kidney problems, or under the age of five. Use during pregnancy or breastfeeding has not been found to cause harm. In the United States the FDA has raised concerns about eye issues in the baby if used during pregnancy. Ethambutol is believed to work by interfering with the bacteria's metabolism.
- Optic neuritis (hence contraindicated in children below six years of age)
- Red-green color blindness People taking ethambutol should be monitored for changes in visual acuity and color discrimination.
- Vertical nystagmus
- Milk skin reaction
Mechanism of action
Ethambutol is bacteriostatic against actively growing TB bacilli. It works by obstructing the formation of cell wall. Mycolic acids attach to the 5'-hydroxyl groups of D-arabinose residues of arabinogalactan and form mycolyl-arabinogalactan-peptidoglycan complex in the cell wall. It disrupts arabinogalactan synthesis by inhibiting the enzyme arabinosyl transferase. Disruption of the arabinogalactan synthesis inhibits the formation of this complex and leads to increased permeability of the cell wall.
It is well absorbed from the gastrointestinal tract and well distributed in body tissues and fluids. 50% is excreted unchanged in urine.
- Hamilton R (2015). Tarascon Pocket Pharmacopoeia (Deluxe Lab-Coat ed.). Jones & Bartlett Learning. p. 48. ISBN 9781284057560.
- "ethambutol (CHEBI:4877)". Chemical Entities of Biological Interest. UK: European Bioinformatics Institute. 18 August 2010. Main. Archived from the original on 19 July 2014. Retrieved 26 April 2012 – via ebi.ac.uk.
- "Ethambutol Hydrochloride". drugs.com. The American Society of Health-System Pharmacists. Archived from the original on 5 June 2016. Retrieved 10 December 2016.
- Stuart MC, Kouimtzi M, Hill SR, eds. (2009). WHO Model Formulary 2008. World Health Organization. pp. 136, 138, 588, 603. hdl:10665/44053. ISBN 9789241547659.
- "Prescribing medicines in pregnancy database". TGA.gov.au. Therapeutic Goods Administration, Department of Health, Australia. 3 March 2014. Archived from the original on 8 April 2014. Retrieved 22 April 2014.
- Landau R, Achilladelis B, Scriabine A (1999). Pharmaceutical Innovation: Revolutionizing Human Health. Chemical Heritage Foundation. p. 171. ISBN 9780941901215. Archived from the original on 2016-12-20.
- World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- Lim SA (April 2006). "Ethambutol-associated optic neuropathy" (PDF). Annals of the Academy of Medicine, Singapore. 35 (4): 274–8. PMID 16710500. Archived (PDF) from the original on 2009-08-16.
- Lewis SM, Dirksen SR, Heitkemper MM, Bucher L, Harding M (5 December 2013). Medical-surgical nursing : assessment and management of clinical problems (9th ed.). St. Louis, Missouri. ISBN 978-0-323-10089-2. OCLC 228373703.
- Tripathi KD (August 2015). Essentials of Medical Pharmacology (Seventh ed.). India: Jaypee Brothers Medical Publishers. p. 769. ISBN 978-93-5025-937-5.